Molecure 과거 수익 실적
과거 기준 확인 0/6
Molecure's earnings have been declining at an average annual rate of -44.8%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 31.2% per year.
주요 정보
-44.8%
수익 성장률
-42.6%
EPS 성장률
Pharmaceuticals 산업 성장 | 29.4% |
매출 성장률 | -31.2% |
자기자본 수익률 | -38.4% |
순이익 | -2,020.9% |
최근 수익 업데이트 | 30 Sep 2024 |
최근 과거 실적 업데이트
Recent updates
Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?
Aug 20Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?
Apr 20We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate
Dec 01Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?
Jul 07Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Mar 10Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Aug 16OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem
Nov 04Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?
Feb 24Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?
Jan 02수익 및 비용 분석
Molecure 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Sep 24 | 2 | -31 | 26 | 0 |
30 Jun 24 | 2 | -30 | 27 | 0 |
31 Mar 24 | 2 | -29 | 27 | 0 |
31 Dec 23 | 4 | -28 | 28 | 0 |
30 Sep 23 | 9 | -45 | 45 | 0 |
30 Jun 23 | 8 | -42 | 41 | 0 |
31 Mar 23 | 8 | -39 | 38 | 0 |
31 Dec 22 | 8 | -36 | 35 | 0 |
30 Sep 22 | 2 | -16 | 16 | 0 |
30 Jun 22 | 2 | -16 | 15 | 0 |
31 Mar 22 | 2 | -15 | 14 | 0 |
31 Dec 21 | 1 | -14 | 12 | 0 |
30 Sep 21 | 124 | 63 | 14 | 0 |
30 Jun 21 | 124 | 64 | 14 | 0 |
31 Mar 21 | 125 | 67 | 12 | 0 |
31 Dec 20 | 125 | 68 | 12 | 0 |
30 Sep 20 | 2 | -3 | 5 | 0 |
30 Jun 20 | 2 | -3 | 5 | 0 |
31 Mar 20 | 2 | -4 | 5 | 0 |
31 Dec 19 | 2 | -4 | 6 | 0 |
30 Sep 19 | 2 | -5 | 6 | 0 |
30 Jun 19 | 2 | -5 | 6 | 0 |
31 Mar 19 | 1 | -5 | 6 | 0 |
31 Dec 18 | 1 | -4 | 5 | 0 |
30 Sep 18 | 1 | -4 | 5 | 0 |
30 Jun 18 | 2 | -4 | 4 | 0 |
31 Mar 18 | 2 | -2 | 4 | 0 |
31 Dec 17 | 1 | -2 | 3 | 0 |
30 Sep 17 | 1 | -3 | 2 | 0 |
30 Jun 17 | 1 | -3 | 2 | 0 |
31 Mar 17 | 1 | -3 | 2 | 0 |
31 Dec 16 | 1 | -2 | 2 | 0 |
31 Dec 15 | 1 | -1 | 1 | 0 |
양질의 수익: MOC is currently unprofitable.
이익 마진 증가: MOC is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: MOC is unprofitable, and losses have increased over the past 5 years at a rate of 44.8% per year.
성장 가속화: Unable to compare MOC's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: MOC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.5%).
자기자본 수익률
높은 ROE: MOC has a negative Return on Equity (-38.4%), as it is currently unprofitable.